February 10, 2020
Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
Experienced executive to lead corneal disease clinical program for TTHX1114
Trefoil Therapeutics today announced the appointment of Thomas M. Tremblay, RN, BSN to the newly created position of Vice President, Clinical Development. He brings to Trefoil more than 25 years of experience in pharmaceutical development across a variety of therapeutic areas.
February 4, 2020
Trefoil Therapeutics Selects AGB Biologics tp Supply Lead Compound TTHX1114
AGC selected based on their proven cGMP capabilities as a manufacturer of protein based therapeutics.
July 16, 2019
Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases
Lead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020
San Diego, California. Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders. The financing included new investors Bios Partners, which led the round, and Access Biotechnology. All existing investors, including Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures and InFocus Capital Partners, participated in this financing. Stella M. Robertson, Ph.D., co-founder of Bios Partners, and a former vice president in Research & Development at Alcon Laboratories, will join Trefoil’s Board of Directors.
March 13, 2017
Trefoil Therapeutics Elects Benjamin F. McGraw, III, to its Board of Directors
As the company's eFGF-1 platform moves forward, Dr. McGraw brings significant high-level experience in development and commercialization
San Diego, California. Trefoil Therapeutics Inc., an early stage biopharmaceutical company focused on developing a regenerative approach to corneal endothelial dystrophies and other diseases, announced today that Benjamin F. McGraw, III, Pharm.D., has been elected to the company’s Board of Directors. Dr. McGraw brings more than 30 years of senior management experience in the life sciences and has been responsible for advancing breakthrough technologies and numerous development-stage programs through commercialization.
January 5, 2017
Trefoil Therapeutics Raises $5.2 Million Series 1 Financing
Hatteras Venture Partners leads round which provides funding to reach IND filing for novel corneal endothelial dystrophy therapy
San Diego, California. Trefoil Therapeutics Inc., an early stage biopharmaceutical company focused on developing a regenerative approach to corneal endothelial dystrophies and other diseases based on novel engineered derivatives of fibroblast growth factor-1 (eFGF-1), announced today the closing of an oversubscribed $5.2 million Series 1 financing lead by Hatteras Venture Partners. In addition to Hatteras Venture Partners, the syndicate included four other firms with significant experience investing in the ophthalmic sector: AJU IB Investment, Correlation Ventures, ExSight Capital and InFocus Capital.
January 3, 2017
Trefoil Therapeutics Enters Into Collaborative Research and Development Agreement with National Institutes of Health’s National Center for Advancing Translational Sciences
TRND Award Will Accelerate the Development of a New Therapy for Fuchs Dystrophy
San Diego, California. Trefoil Therapeutics, a privately funded company focused on improving human health and creating new therapies using drugs developed with protein engineering, announced today it will collaborate with the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) to complete the Investigational New Drug (IND) enabling activities for their lead compound, TTHX1114, toward a treatment for Fuchs endothelial corneal dystrophy (FECD).
January 27, 2016
Trefoil Therapeutics Announces Completion of Pre-IND Meeting with FDA for TTHX-1114 for the Treatment of Corneal Endothelial Dystrophies
Guidance Provides a Clear Path for the Filing of an IND and Clinical Proof of Concept Studies
San Diego, California. Trefoil Therapeutics, an early stage biopharmaceutical company focused on developing a regenerative approach to corneal endothelial dystrophies and other diseases based on novel engineered derivatives of fibroblast growth factor-1 (eFGF-1) announced completion of a pre-IND meeting with the FDA that took place on January 20 regarding Trefoil’s lead product candidate, TTHX-1114 for the treatment of bullous keratopathy and Fuchs Dystrophy, diseases that are currently treated by corneal transplantation.
October 20, 2015
Trefoil Therapeutics and E&B Technologies Awarded NIH R21 Grant for Evaluation of Engineered FGF-1 Derivatives as Therapy for Ocular Surface Injury
Expands Research from Endothelial to Epithelial Cell Regeneration
San Diego, California. Trefoil Therapeutics and and E&B Technologies announced today that the National Institute of Health has awarded a two year grant under the CounterACT (Countermeasures Against Chemical Threats) program for the study of engineered fibroblast growth factor (eFGF-1) derivatives as a therapy for ocular surface injury as a result of mustard gas exposure.
April 30, 2015
Trefoil Therapeutics To Present Data on Novel Class of Engineered FGF-1 Compounds at ARVO 2015 Meeting
Engineered FGF-1 Derivatives Stimulate Proliferation of Corneal Endothelial Cells
San Diego, California. Trefoil Therapeutics today announced that David Eveleth, PhD will present new data supporting the potential utility of engineered FGF-1s (eFGF-1s) in ocular disease at a poster at the Association for Research in Vision and Ophthalmology (ARVO) 2015 annual meeting in Denver, CO on Sunday, May 3, 2015 at 3:15 p.m. (Session 1169, Poster #D0071).
March 24, 2015
Trefoil Therapeutics Announces the Signing of a License and Research Agreement with Florida State University for Engineered FGF-1 Derivatives
Development Program to Focus on the Treatment of Corneal Dystrophies
Trefoil Therapeutics today announced the signing of a license and research agreement with Florida State University for the development of engineered FGF-1 derivatives (eFGF-1s). This agreement gives Trefoil an exclusive license to the eFGF-1 patent estate for therapeutic and cosmetic uses. This collaboration will advance the existing eFGF-1 technology developed by Dr. Michael Blaber, Professor at FSU and a co-founder of Trefoil.